{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:22:33Z","timestamp":1780662153678,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273540"],"award-info":[{"award-number":["81273540"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472684"],"award-info":[{"award-number":["81472684"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042017KF0242"],"award-info":[{"award-number":["2042017KF0242"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejphar.2020.173575","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T16:29:21Z","timestamp":1600360161000},"page":"173575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner"],"prefix":"10.1016","volume":"888","author":[{"given":"Han","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173575_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","article-title":"Mitochondria-judges and executioners of cell death sentences","volume":"61","author":"Bhola","year":"2016","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejphar.2020.173575_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejphar.2020.173575_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejphar.2020.173575_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8110319","article-title":"Tenuifolide B from cinnamomum tenuifolium stem selectively inhibits proliferation of oral cancer cells via apoptosis, ROS generation, mitochondrial depolarization, and DNA damage","volume":"8","author":"Chen","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.ejphar.2020.173575_bib5","first-page":"2079","volume":"vol. 176","author":"Chen","year":"2019"},{"key":"10.1016\/j.ejphar.2020.173575_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064739","article-title":"Golden berry-derived 4\u03b2-hydroxywithanolide E for selectively killing oral cancer cells by generating ROS, DNA damage, and apoptotic pathways","volume":"8","author":"Chiu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173575_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.tcb.2016.11.004","article-title":"Bax and Bak pores: are we closing the circle?","volume":"27","author":"Cosentino","year":"2017","journal-title":"Trends Cell Biol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2020.173575_bib8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10637-010-9596-y","article-title":"Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect","volume":"28","author":"Dickinson","year":"2010","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2020.173575_bib9","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/1535-7163.MCT-17-1240","article-title":"Induction of thioredoxin-interacting protein by a histone deacetylase inhibitor, entinostat, is associated with DNA damage and apoptosis in esophageal adenocarcinoma","volume":"17","author":"Feingold","year":"2018","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173575_bib10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tcb.2013.07.006","article-title":"Evading apoptosis in cancer","volume":"23","author":"Fernald","year":"2013","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejphar.2020.173575_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0959-8049(01)00356-2","article-title":"The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7\/adr cells","volume":"38","author":"Fu","year":"2002","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173575_bib12","doi-asserted-by":"crossref","first-page":"35576","DOI":"10.1074\/jbc.M112.370585","article-title":"Autophagy-related gene 7 (ATG7) and reactive oxygen species\/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma","volume":"287","author":"Gong","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2020.173575_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2020.173575_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173575_bib15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","article-title":"MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent","volume":"39","author":"Hess-Stumpp","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejphar.2020.173575_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1466018","article-title":"Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types","volume":"7","author":"Hicks","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejphar.2020.173575_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0166-5","article-title":"Honokiol induces apoptosis and autophagy via the ROS\/ERK1\/2 signaling pathway in human osteosarcoma cells in vitro and in vivo","volume":"9","author":"Huang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2020.173575_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2008.03.011","article-title":"Redox-based regulation of signal transduction: principles, pitfalls, and promises","volume":"45","author":"Janssen-Heininger","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2020.173575_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","article-title":"The p53 pathway: Origins, inactivation in cancer, and emerging therapeutic approaches","volume":"85","author":"Joerger","year":"2016","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejphar.2020.173575_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejphar.2020.173575_bib21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173575_bib22","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/13543784.2011.613822","article-title":"Entinostat for treatment of solid tumors and hematologic malignancies","volume":"20","author":"Knipstein","year":"2011","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2020.173575_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ijc.25817","article-title":"Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma","volume":"129","author":"Liu","year":"2011","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173575_bib24","doi-asserted-by":"crossref","first-page":"40800","DOI":"10.18632\/oncotarget.8315","article-title":"Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2020.173575_bib25","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/bph.13045","article-title":"Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21","volume":"172","author":"Mei","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173575_bib26","article-title":"Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise","author":"Morel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2020.173575_bib27","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1111\/febs.13746","article-title":"How do tumor cells respond to HDAC inhibition?","volume":"283","author":"Newbold","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2020.173575_bib28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bjc.6604557","article-title":"Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?","volume":"99","author":"Nolan","year":"2008","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173575_bib29","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/stem.1398","article-title":"Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia","volume":"31","author":"Ramsey","year":"2013","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejphar.2020.173575_bib30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1476-5381.2009.00605.x","article-title":"Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1\/2 signalling","volume":"159","author":"Shen","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173575_bib31","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-17-1157","article-title":"Tetrandrine (TET) induces death receptors apo trail R1 (DR4) and apo trail R2 (DR5) and sensitizes prostate cancer cells to TRAIL-induced apoptosis","volume":"17","author":"Shishodia","year":"2018","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173575_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2018.03.042","article-title":"Tetrandrine inhibits deregulated cell cycle in pancreatic cancer cells: differential regulation of p21(Cip 1\/Waf1), p27(Kip 1) and cyclin D1","volume":"425","author":"Singh","year":"2018","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejphar.2020.173575_bib33","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1535-7163.MCT-10-0582","article-title":"MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo","volume":"9","author":"Srivastava","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173575_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews","volume":"8","author":"Trachootham","year":"2009","journal-title":"Drug discovery"},{"key":"10.1016\/j.ejphar.2020.173575_bib35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nrd2656","article-title":"The genetics of the p53 pathway, apoptosis and cancer therapy","volume":"7","author":"Vazquez","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2020.173575_bib36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bjc.2013.334","article-title":"Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)\/Akt signaling","volume":"109","author":"Wan","year":"2013","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173575_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tips.2004.01.009","article-title":"Herbal alkaloid tetrandrine: from an ion channel blocker to inhibitor of tumor proliferation","volume":"25","author":"Wang","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.173575_bib38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","article-title":"Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death","volume":"292","author":"Wei","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173575_bib39","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2011.38.9411","article-title":"Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy","volume":"30","author":"Witta","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2020.173575_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0498-9","article-title":"c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2020.173575_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2009.06.009","article-title":"Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice","volume":"287","author":"Wu","year":"2010","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejphar.2020.173575_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-018-0779-2","article-title":"Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy","volume":"37","author":"Yu","year":"2018","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.ejphar.2020.173575_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2011.01.022","article-title":"Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo","volume":"304","author":"Zhang","year":"2011","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejphar.2020.173575_bib44","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/leu.2012.366","article-title":"HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur 77 and Nor 1 and of key pro-apoptotic proteins in AML","volume":"27","author":"Zhou","year":"2013","journal-title":"Leukemia"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:25:30Z","timestamp":1747844730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920306671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":44,"alternative-id":["S0014299920306671"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173575","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173575"}}